Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLBENEMID vs CEPHULAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Colchicine inhibits microtubule polymerization, reducing neutrophil chemotaxis and inflammation. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion.
Lactulose, a synthetic disaccharide, is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form short-chain fatty acids (e.g., lactic, acetic, formic acids), which acidify the colonic contents. In hepatic encephalopathy, the acidic environment converts ammonia (NH3) to ammonium (NH4+), which is poorly absorbed and excreted in feces. Additionally, the osmotic effect of lactulose draws water into the colon, softening stools and increasing bowel movements.
Prophylaxis and treatment of acute gout flares,Hyperuricemia associated with gout (probenecid component)
Treatment of constipation,Hepatic encephalopathy (portal-systemic encephalopathy) including the prevention and treatment of coma
Adults: 1 tablet (probenecid 500 mg / colchicine 0.5 mg) orally once daily for first week, then twice daily thereafter. May increase to 3-4 tablets daily in divided doses if needed.
30-45 m L (6.67-10 g lactulose) orally 3-4 times daily for constipation; for hepatic encephalopathy, 30-45 m L orally 3-4 times daily titrated to produce 2-3 soft stools per day, or 300 m L in 700 m L of water or saline as retention enema for 30-60 min every 4-6 hours.
Probenecid: 6-12 hours (dose-dependent); colchicine: 20-30 hours (terminal) in renal impairment may prolong.
Terminal elimination half-life is 7-10 hours (renal impairment: prolonged); systemic absorption is minimal (<3%) after oral administration, so half-life reflects clearance of absorbed fraction.
Colchicine: primarily hepatic via CYP3A4; Probenecid: hepatic metabolism via glucuronidation and oxidation.
Not absorbed; metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to low molecular weight organic acids.
Renal: ~76% as unchanged probenecid and metabolites; biliary/fecal: minor (<5%). Colchicine: ~20% renal, ~80% fecal primarily via biliary excretion.
Primarily renal (20-30% as unchanged drug) and fecal (up to 70% as unmetabolized drug via biliary elimination; following gastric acid-mediated degradation, only 5-10% reaches urine as intact lactulose; hepatic metabolism is negligible).
Probenecid: ~85-95% primarily to albumin; colchicine: ~30-50% to albumin and other proteins.
Negligible (<5%): lactulose does not bind significantly to albumin or other plasma proteins due to its hydrophilic nature.
Probenecid: 0.15-0.2 L/kg (confined to plasma and extracellular fluid); colchicine: 2-8 L/kg (wide tissue distribution, high in leukocytes).
0.5-1.0 L/kg (estimated from systemic absorption studies; limited data due to minimal absorption; reflects distribution largely into extracellular water).
Probenecid: ~100% oral; colchicine: ~45% oral (range 25-50%) with significant first-pass metabolism.
Oral: <3% (due to poor absorption and extensive metabolism by colonic bacteria; most of the drug remains in the gut lumen). Rectal: similar to oral, as systemic absorption is minimal.
Cr Cl <50 m L/min: contraindicated. Cr Cl 50-80 m L/min: reduce dose by 50% or extend interval. Cr Cl >80 m L/min: no adjustment.
No dose adjustment required for renal impairment as lactulose is minimally absorbed and primarily acts locally in the colon.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or use with caution. Child-Pugh C: contraindicated (risk of colchicine accumulation).
Not specifically adjusted based on Child-Pugh score; dose is titrated to achieve desired stool frequency; caution in severe hepatic impairment due to risk of electrolyte disturbances.
Not recommended for pediatric use; safety and efficacy not established.
Infants: 2.5-10 m L/day in divided doses; older children: 10-25 m L/day; adolescents: 15-30 m L/day; all for constipation; for hepatic encephalopathy, doses as low as 5-10 m L 3-4 times daily with dose adjusted to produce 2-3 soft stools per day.
Start at lowest dose (e.g., 1 tablet daily) and titrate slowly; monitor renal function and avoid in Cr Cl <50 m L/min. Consider reduced doses due to increased risk of toxicity.
Initiate at lower end of dosing range (15-30 m L/day) due to increased risk of dehydration and electrolyte imbalance; monitor for diarrhea and adjust accordingly.
No FDA boxed warning.
None
Severe toxicity with colchicine in renal/hepatic impairment; blood dyscrasias (probenecid); increased risk of colchicine toxicity with CYP3A4 inhibitors; avoid use with NSAIDs due to increased GI toxicity.
Electrolyte imbalance with prolonged use, especially in debilitated patients,Diarrhea may cause fluid and electrolyte loss,Galactose intolerance (contraindicated in patients requiring low galactose diet due to lactose content in some preparations),Monitor serum electrolytes in patients receiving high doses for hepatic encephalopathy
Hypersensitivity to colchicine or probenecid; severe renal impairment (Cr Cl < 30 m L/min); concurrent use of P-glycoprotein or strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) with colchicine; blood dyscrasias; peptic ulcer disease; acute gout flare treatment with history of uric acid renal calculi.
Patients requiring a low-galactose diet (lactulose contains galactose and lactose),Intestinal obstruction,Suspected gastrointestinal obstruction or perforation
Alcohol reduces efficacy and increases hyperuricemia; avoid completely. High-purine foods (e.g., red meat, organ meats, sardines, mussels) may exacerbate gout. Grapefruit juice may increase colchicine toxicity via CYP3A4 inhibition. Acidic foods (e.g., cranberries, prunes) can decrease urine p H and increase uric acid crystallization risk. Maintain adequate hydration with water.
No specific food interactions. Avoid concurrent use with other laxatives unless directed. High-fiber foods may enhance effect; ensure adequate fluid intake.
Colbenemid is a combination of colchicine and probenecid. Colchicine is associated with increased risk of fetal harm when administered during pregnancy, including chromosomal abnormalities and fetal death, particularly in the first trimester. Probenecid should be avoided in pregnancy due to potential teratogenic effects and neonatal toxicity. Overall, use is contraindicated in pregnant women.
Lactulose (CEPHULAC) is not absorbed systemically; therefore, fetal exposure is negligible. Animal studies have not shown teratogenic effects. In clinical practice, no fetal risks have been identified in any trimester.
Colchicine is excreted into human milk with a milk-to-plasma ratio (M/P ratio) of approximately 0.9. Probenecid passes into breast milk in small amounts. Due to potential serious adverse effects in nursing infants, including gastrointestinal toxicity and bone marrow suppression, breastfeeding is not recommended during therapy.
Lactulose is not excreted into breast milk due to minimal systemic absorption. It is considered compatible with breastfeeding. M/P ratio: Not applicable (negligible absorption).
No specific dose adjustment guidelines exist due to contraindication during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased renal clearance) may reduce efficacy, but use is not recommended.
No dose adjustment required. Pharmacokinetics are unchanged in pregnancy due to lack of systemic absorption. Standard dosing of 15-30 m L (10-20 g) once daily, up to 60 m L/day in divided doses, is appropriate.
Colbenemid is a fixed-dose combination of colchicine (0.5 mg) and probenecid (500 mg). Probenecid increases uric acid excretion by inhibiting renal tubular reabsorption; colchicine reduces gout flare inflammation. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) or peptic ulcer disease. Probenecid can increase serum levels of penicillins, cephalosporins, and NSAIDs. Colchicine toxicity risk increases with concurrent P-glycoprotein or CYP3A4 inhibitors (e.g., clarithromycin, cyclosporine). Monitor for myopathy and neuropathy. May cause a false-positive urinary glucose test.
Cephulac (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. In hepatic encephalopathy, titrate to produce 2-3 soft stools per day. Monitor serum electrolytes, especially in elderly or renal impairment. Onset of action for constipation may be 24-48 hours. Do not confuse with other lactose-containing products.
Take with food or milk to reduce gastrointestinal upset.,Drink at least 2-3 liters of fluid daily to prevent kidney stones.,Avoid alcohol and high-purine foods (organ meats, shellfish) during therapy.,Report signs of toxicity: muscle weakness, numbness, tingling, severe diarrhea, or vomiting.,Do not take with macrolide antibiotics or antifungal medications without consulting your doctor.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; may take 24-48 hours to produce a bowel movement.,For hepatic encephalopathy, maintain 2-3 soft stools daily; do not skip doses.,May cause bloating, gas, or cramping initially; usually resolves.,Do not take other laxatives without consulting your doctor.,Report severe diarrhea, vomiting, or muscle cramps to your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLBENEMID vs CEPHULAC, answered by our medical review team.
COLBENEMID is a Antigout Agent Combination that works by Colchicine inhibits microtubule polymerization, reducing neutrophil chemotaxis and inflammation. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion.. CEPHULAC is a Laxative that works by Lactulose, a synthetic disaccharide, is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form short-chain fatty acids (e.g., lactic, acetic, formic acids), which acidify the colonic contents. In hepatic encephalopathy, the acidic environment converts ammonia (NH3) to ammonium (NH4+), which is poorly absorbed and excreted in feces. Additionally, the osmotic effect of lactulose draws water into the colon, softening stools and increasing bowel movements.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLBENEMID and CEPHULAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLBENEMID is: Adults: 1 tablet (probenecid 500 mg / colchicine 0.5 mg) orally once daily for first week, then twice daily thereafter. May increase to 3-4 tablets daily in divided doses if needed.. The standard adult dose of CEPHULAC is: 30-45 m L (6.67-10 g lactulose) orally 3-4 times daily for constipation; for hepatic encephalopathy, 30-45 m L orally 3-4 times daily titrated to produce 2-3 soft stools per day, or 300 m L in 700 m L of water or saline as retention enema for 30-60 min every 4-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLBENEMID and CEPHULAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLBENEMID is classified as Category C. Colbenemid is a combination of colchicine and probenecid. Colchicine is associated with increased risk of fetal harm when administered during pregnancy, including chromosomal abnor. CEPHULAC is classified as Category C. Lactulose (CEPHULAC) is not absorbed systemically; therefore, fetal exposure is negligible. Animal studies have not shown teratogenic effects. In clinical practice, no fetal risks . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.